Implementation of MISSION–Criminal Justice in a Treatment Court: Preliminary Outcomes Among Individuals With Co-occurring Disorders

This pilot study examined the preliminary effectiveness of MISSION-CJ with mental health court participants. To be eligible for this mental health court, individuals had to be age 18 or older; have criminal charges in the district court with possibility of incarceration; have a confirmed mental illness or present with symptoms suggesting a mental illness or a co-occurring disorder with substance use; have a guilty finding for the criminal charges with a probation sentence or already be on probation with a violation of probation notice; and agree to comply with program requirements. The mental health court serves individuals with a variety of psychiatric diagnoses and criminal charges. Approximately 70% of participants in this mental health court had co-occurring disorders; the most common diagnoses were bipolar disorder, schizophrenia or schizoaffective disorder, major depression, and posttraumatic stress disorder (PTSD). At least 50% had multiple past violent and nonviolent crimes, ranging from offenses against property and people to prostitution and drug-related offenses, and many had violated terms of probation.

Participant eligibility for MISSION-CJ was determined after a referral for screening for clinical eligibility. Participants who had new offenses met with their attorneys to determine whether participation in the mental health court in general, and participation in MISSION-CJ services specifically, made sense for their defense, and participants facing probation violations made similar determinations prior to the legal disposition. Judicial orders for participation at case adjudication were the formal initiation of services, although participation was considered voluntary for defendants as an alternative to incarceration. In addition to meeting these mental health court criteria, to enroll in MISSION-CJ, individuals also had to meet criteria for a DSM-IV-TR axis I psychiatric disorder (gathered from court or provider records) and have past or current substance use. Individuals with acute psychiatric or medical conditions, including active psychosis, acute suicidality, acute substance use treatment needs, or severe intellectual or developmental disability or cognitive impairment, were excluded from participation in MISSION-CJ. In addition, given that MISSION-CJ and the mental health court were considered postadjudication interventions, individuals who were deemed incompetent to stand trial by the court were ineligible to enroll. Ineligible participants received treatment as usual within the court, which mainly consisted of service linkages and unstructured contact provided by probation officers or the case manager assigned to the specialty court rather than the specified structured care and linkage provided by the MISSION-CJ model.

This project was approved by both of the relevant state and university institutional review boards (IRBs). Both IRBs waived requirements for informed consent because this study was a program evaluation. Once enrolled in MISSION-CJ, participants completed a comprehensive baseline assessment, which included the Addiction Severity Index (11), the Behavior and Symptom Identification Scale-32 (BASIS-32) (12), the PTSD Checklist–Civilian Version (PCL-C) (13), and the Government Performance and Results Act Discretionary Services Tool (14). This assessment was readministered 6 months after the baseline assessment. This study includes baseline and 6-month follow-up data collected from March 2015 through October 2017.

Analyses were computed via IBM SPSS Statistics (version 22.0). We measured baseline participant characteristics via frequency and descriptive analyses. For pre- and posttest outcomes, we conducted normality tests on continuous measures. Because the data were not normally distributed, we used Wilcoxon signed-rank tests to analyze 6-month postenrollment outcomes across all pre- and posttest continuous measures.

Baseline participant characteristics are presented in the online supplement. The participants (N=97) were racially and ethnically diverse: 49% (N=48) were Hispanic/Latino; 51% (N=49), non-Hispanic/Latino; 37% (N=33), African American; 1% (N=1), Native American; 53% (N=48), Caucasian; and 9% (N=8), multiracial. Participants were primarily male (80%), with a mean±SD age of 34.18±10.05 years (median=33.00 years, minimum=19 years, maximum=60 years). During their lifetime, participants experienced 12.02±11.78 arrests (median=8.00 arrests, minimum=1 arrest, maximum=60 arrests) and spent 60.28±81.24 months incarcerated (median=24.50 months, minimum=0 months, maximum=456 months). Ninety-one percent (N=84 of 91 with available data) of participants reported experiencing serious depression for a significant period of their life, and participants reported a lifetime mean of 13.94±8.63 years of illegal drug use (median=11.00 years, minimum=0 years, maximum=40 years).

Pre- and posttest outcomes data are presented in Table 1. Participant data indicated that nights incarcerated were significantly reduced from a mean of 58.30 nights incarcerated (median=37.00 nights, minimum=0 nights, maximum=180 nights) in the 6 months prior to enrollment in MISSION-CJ to a mean of 28.10 nights (median=0.00 nights, minimum=0 nights, maximum=180 nights) after 6 months of enrollment (z=–3.430, p<0.002). Moreover, the total BASIS-32 (12) score revealed a significant reduction in behavioral health symptoms, from a mean score of 0.61 (median=0.41, minimum=0.00, maximum=1.75) at enrollment to a mean score of 0.45 (median=0.34, minimum=0.00, maximum=1.44) after 6 months of enrollment (z=–2.777, p<0.006). Furthermore, the number of days of illegal drug use decreased from a mean of 55.28 days (median=18 days, minimum=0 days, maximum=180 days) during the 6 months before enrollment to a mean of 34.74 days (median=2.00 days, minimum=0 days, maximum=180 days) after 6 months of enrollment (z=–3.031, p<0.003). Last, the PCL-C (13) score demonstrated a significant reduction in PTSD symptoms from a mean score of 37.66 (median=35.00, minimum=17, maximum=81) at enrollment to a mean score of 29.04 (median=25.00, minimum=17, maximum=76) after 6 months of enrollment (z=–2.939, p<0.004).

The data showed that at the 6-month follow-up assessment, mental health court participants receiving the MISSION-CJ intervention had several areas of positive change. For example, positive outcomes were seen in criminal justice involvement, as well as in some behavioral health symptoms, including trauma symptoms and substance use. Our findings are consistent with a prior open pilot test of MISSION-CJ in a drug court setting, where improved criminal justice and substance use outcomes were shown (15). Although many models of support interventions are available to address the needs of justice-involved individuals with co-occurring disorders, behavioral health and criminal justice system staff and administrators repeatedly express having insufficient guidance and skill in working with these populations. The MISSION-CJ intervention uniquely addresses this issue through augmenting wraparound general support with the following key elements: a manualized approach that guides structured and unstructured service delivery specific to individuals with co-occurring disorders; an RNR treatment planning support tool that promotes progress and positive outcomes around criminogenic risks and needs, such as decreased recidivism and increased prosocial behavior and thinking; a curriculum that promotes prosocial behavior and thinking; and behavioral health teams consisting of a case manager and peer specialist who partner with and are trained and supported to work directly with community supervision (i.e., probation officers).

MISSION-CJ also has a strong staff development component to address gaps in knowledge and skills for administrators and staff members, including regular fidelity monitoring and feedback to inform quality monitoring and staff training needs. This component furthers the program’s ability to guide staff supervision and support and to foster positive engagement between behavioral health providers and criminal justice staff to achieve better outcomes for the individuals served and the public. The improvements observed in these key outcomes may reflect the ability of MISSION-CJ to meet the complex needs of justice-involved individuals, who are often caught between the criminal justice and behavioral health systems, by integrating both behavioral and criminogenic risks and needs during treatment planning. For example, the MISSION-CJ model allows flexibility to increase service intensity for participants with high risks and needs, such as providing booster DRT sessions focused on criminogenic needs (7, 9). Our outcomes may also suggest the positive impact of a boundary spanning intervention and support work by Steadman and colleagues (10), who cite boundary spanning as a central feature of effective diversion programs for justice-involved individuals with co-occurring disorders.

Several limitations of this pilot study should be acknowledged. The sample size was small. Additionally, participants entered the mental health court postadjudication after consulting with their attorneys and deciding that the alternative to incarceration of intensive treatment and community supervision was worthwhile; thus the participants may have constituted a somewhat homogeneous sample. Study data showed that almost three-quarters of participants were motivated to join the program to avoid possible criminal punishment; motivation and stage of change in this population should be explored in future studies. Our study also did not tease apart the therapeutic effects of MISSION-CJ compared with the impact of court mandates. Also, model fidelity, measured during the implementation but beyond the scope of this article, would require further assessment relative to outcomes. Last, and perhaps most critical, given the preliminary nature of the study, we did not have a comparison group, nor did we use randomization to explore results for mental health court participants who did not receive MISSION-CJ as an augmentation to treatment as usual.

Despite these limitations, this pilot study demonstrates that the MISSION-CJ intervention could be offered to mental health court participants as a community-based but behavioral health- and criminal justice-integrated service alongside the mental health court, with promising preliminary results. The behavioral health and criminal justice systems are beginning to learn to work together, but all too often they operate in separate silos with different goals and approaches while working with the same individuals. MISSION-CJ attempts to cross those boundaries and target what Wolff and colleagues (6) called the next generation in interventions for these challenging populations—promoting recovery, reducing recidivism, and avoiding the “revolving door” in which, historically, justice-involved individuals with co-occurring disorders repeatedly cycle through the criminal justice system (4). Future studies comparing the effectiveness and cost-effectiveness of MISSION-CJ, usual mental health court processes, and any alternative interventions are needed to address the needs of this growing population.

The authors thank Behavioral Health Network, Inc., the University of Massachusetts Medical School, the Executive Office of the Trial Court, and the Massachusetts Department of Mental Health, the grant recipient, for supporting this work.